Fixed-dose combinations as initial therapy for hypertension : a review of approved agents and a guide to patient selection.

Détails

ID Serval
serval:BIB_C155421D95AC
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Fixed-dose combinations as initial therapy for hypertension : a review of approved agents and a guide to patient selection.
Périodique
Drugs
Auteur(s)
Waeber B., Feihl F., Ruilope L.M.
ISSN
0012-6667
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
69
Numéro
13
Pages
1761-1776
Langue
anglais
Résumé
Recent guidelines recommend initiation of antihypertensive therapy with fixed-dose combinations in high-risk patients because such patients usually need two or more blood pressure (BP)-lowering agents in order to normalize their BP. Agents that block the renin-angiotensin system (ACE inhibitors or angiotensin II receptor antagonists [angiotensin receptor blockers; ARBs]) are preferred for the management of hypertension in most patients exhibiting subclinical target organ damage, or established cardiovascular or renal diseases. Unless contraindicated they should be one of the components of fixed-dose combinations, whereas the other component may be either a calcium channel antagonist or a thiazide diuretic. Fixed-dose combinations containing an ACE inhibitor or ARB plus a calcium channel antagonist appear particularly effective in preventing complications of coronary heart disease.
Mots-clé
Blood-Pressure Control , Randomized Controlled-Trial, Major Cardiovascular Events, Verapamil Sr-Trandolapril, Calcium-Channel Blockade, Renin-Angiotensin System, To-Moderate Hypertension, Placebo-Controlled Trial, Coronary-Artery-Disease, High-Risk Patients
Pubmed
Web of science
Création de la notice
29/10/2009 9:22
Dernière modification de la notice
20/08/2019 15:36
Données d'usage